Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
ASH 2019 – CLL
ASH 2019 – CLL
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab for First-Line Treatment of CLL with IGHV Mutation and without Del(17p)/Mutated TP53
ASH 2019 – CLL
Read More ›
Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia
ASH 2019 – CLL
Read More ›
Page 4 of 4
1
2
3
4
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us